

## ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 12/21/09 wherein claims 1 and 7 were amended and claims 3-6 were canceled.

## EXAMINER'S AMENDMENT

2. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Craig Bohlken on 3/23/10.

The application has been amended as follows:

In the specification, page 7, after line 5, insert

--Brief Description of the Drawing

Figure 1 is an illustration of the Renin Angiotensin Aldostrone System (RAAS).--.

Claim 1, line 1, replace 'Pharmaceutical *characterized by* the formula (I)' with --A compound of Formula I--.

Cancel claim 2.

Claim 7, lines 1-2, replace 'Pharmaceuticals of claim 1 having the formulas (X) or (XII)' with --Compounds of claim 1 having the structures--.

Claim 7, delete line 7.

Claim 7, in between lines 9 and 10, insert --or--.

Claim 7, line 11, after 'Formula (XIIa)' insert --,--

Claim 8, line 1, replace 'Pharmaceutical' with --A pharmaceutical--.

Replace claim 9 with the following.

9. (Currently Amended) A method of treating heart failure, cardiac arrhythmias, COPD (chronic obstructive pulmonary disease), liver fibrosis, and atherosclerosis comprising administering a compound of claim 1 to a person in need thereof.

Replace claim 10 with the following.

10. (Currently Amended) A method of *in vivo* diagnosis of heart failure, cardiac arrhythmias, COPD (chronic obstructive pulmonary disease), liver fibrosis, and atherosclerosis comprising administering a compound of claim 1 to a subject and generating an image of part or all of said subject.

Replace claim 11 with the following.

11. (Currently Amended) A kit for the preparation of a radiopharmaceutical formulation comprising a compound of claim 1 and a reducing agent.

#### **ALLOWABLE CLAIMS**

3. The claims are distinguished over the prior art of record because the prior art neither anticipates nor renders obvious compounds and uses thereof having Formula I.

4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D L. Jones whose telephone number is (571)272-0617. The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/D L. Jones/  
Primary Examiner  
Art Unit 1618

March 23, 2010